2 nd Cancer Pain Symposium Opiate Related Side Effects: Focus on Constipation Lydia Mis, PharmD, BCOP Clinical Oncology Pharmacist June 6, 2008 Duke University.

Slides:



Advertisements
Similar presentations
Pain Control in Hospice and Palliative Care
Advertisements

Constipation and the Cancer Patient
Opioids and other drugs we use on palliative care
Constipation Prepared by: Alison Deux, 4th year pharmacy student.
Palliative Sedation Pam Mansfield, MD, CCFP October 2, 2009.
What to Do About Pain Nirmala Abraham Hidalgo, MD Assistant Director, UCLA Pain Management Center Assistant Professor, Dept. of Anesthesiology UCLA - David.
Intern Basics- Part II Jacobi medical Center. Falls Assess the patient after the fall Assess the patient after the fall Witnessed or not Witnessed or.
Constipation and Diarrhea Elizabeth Whiteman M.D..
Pain Management Part 2 Use of Adjuvants John Mulder, MD, FAAHPM Vice President of Medical Services Faith Hospice Director, GR MEP Palliative Medicine Fellowship.
Key dosing points: Begin a bowel regimen when opioid therapy is initiated (senna + docusate). For CHRONIC pain, use a scheduled medication regimen. ( ex:
Calvin Lui, MD PGY2 February 8,  Common Opioid Agents and Good Starting Dosages  Opioid Conversion  Use of Patient Controlled Analgesia and Good.
Sublingual Buprenorphine and Pain
P Sylvester (MBBS),D Narinesingh (MBBS,MMed,FCRadOnc)
SYRINGE DRIVERS Coranne Rice.
Mosby items and derived items © 2005, 2002 by Mosby, Inc. CHAPTER 51 Antiemetic and Antinausea Agents.
The Prostate Net Pain management for patients and caregivers Biren Saraiya MD The Cancer Institute of New Jersey.
Assessment and Management of Constipation
Chemotherapy Induced Nausea and Vomiting
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
Chapter 10 Analgesics and Antipyretics. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Pain When.
JUST NAUSEA ? Symptom management. JUST NAUSEA ? OBJECTIVES Identify the effects of Nausea on daily life Identify those palliative patients at greatest.
CARE OF DYING PATIENT Dorothy D. Sherwood, M.D. 6/11/2005.
Seminar in Palliative Care September 26 – October 02, 2010 Salzburg, Austria in Collaboration with.
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
Prepared by : Areen Zraikah Dana Fatayer. Pharmacology: Naloxone and nalmefene are pure opioid antagonists that competitively block mu, kappa, and delta.
Pain Most common reason people seek health care Tissue damage activates free nerve endings (pain receptors) Generally indicates tissue damage.
The Basics of Symptom Management: Understanding, Assessment and Principles Dr. Leah Steinberg.
Plasma concentration Time PO: C max ~ 60 minutes (oxymorphone ~ 30 minutes ) SQ: C max ~ 30 minutes IV: C max ~6 minutes Pharmacologic administration curves.
A logical method for hospital- based pain treatment Bob Arnold MD Institute to Enhance Palliative Care.
End of Life Symptom Management Dec 3, 2014 Mudit Dabral Rosene Pirrello.
 72 M, acute femoral fracture. History of hip, knee OA. Uses Tylenol, ibuprofen.  Used Norco in the past very infrequently. Keeps an old bottle in the.
C C E E N N L L E E Pediatric Palliative Care Analgesics NSAIDs  Cyclooxygenase inhibition leads to interference with production of PGs (Cox-2)  Decreased.
Prim. mag. Marija Cesar Komar dr.med. 1st Congress of the Slovenian Association for Pain Therapy and Symposium on Clinical Neurophysiology of Pain Bled,
EPECEPECEPECEPEC GI Symptoms Module 10a The Education in Palliative and End-of-life Care program at Northwestern University Feinberg School of Medicine,
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 53 Antiemetic and Antinausea Drugs.
Using Opioids in the Hospitalized Patient Nicole Artz, MD Assistant Professor of Medicine University of Chicago No financial relationships to disclose.
1. What is the most common cause of constipation? A.Pelvic floor dyssynergia B.Slow transit C.Functional D.Mechanical obstruction.
Constipation: The Latest and Greatest Rosene Pirrello, RPh Solomon Liao, MD.
Side effects and toxicity of analgesics Disclaimer: This presentation contains information on the general principles of pain management. This presentation.
Drugs Used to Treat Nausea and Vomiting Chapter 34 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Pain II: Cancer Pain Management Dr. Leah Steinberg.
Laxatives and Antidiarrheals
UCLA Brain Institute Outreach Adrina Kocharian and Rachel Oseas.
Palliative Care: Non pain symptoms Elizabeth Whiteman, M.D.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
Foundation Teaching Wendy Caddye Senior CNS Acute Pain.
Inadequately treated acute pain can lead to prolonged hospital stay, delayed recovery, psychological consequences, increased costs and the development.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
What is Palliative Care? n Support and comfort for individuals and families living with chronic or life- threatening illnesses n Focuses on: –Relieving.
GP Clinical Governance Meeting 13 th of July 2011 Dr Marion Lieth Consultant in Palliative Medicine, Bolton Hospital and Bolton Hospice Common issues:
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
Management: Spinal Cord Compression
Chapter 13 Pain Management.
Jeopardy Final Jeopardy Antacids Antiemetics/ Emetics $100 $100 $100

Opiod analgesics 9월 흉부외과 인턴 김영재.
Section IV: Principles of Pain Management
Pain and Symptom Management
Palliative Care in the Outpatient Setting: Pain Management
STOP! Safe Treatment of Pain
Opioids and other drugs we use in palliative care
Introduction to Clinical Pharmacology Chapter 16 Opioid Antagonists
THE MODERN MANAGEMENT OF PAIN IN PALLIATIVE MEDICINE
Other Gastrointestinal Drugs
How do I manage pain and agitation?
School of Pharmacy, University of Nizwa
School of Pharmacy, University of Nizwa
Introduction to Clinical Pharmacology Chapter 16 Opioid Antagonists
Intern Bootcamp 2019: PAIN & POOOOOOOP Doug Hutcheon, MD July, 2019
Pain Management Top 10 Resident Pitfalls- 2019
Presentation transcript:

2 nd Cancer Pain Symposium Opiate Related Side Effects: Focus on Constipation Lydia Mis, PharmD, BCOP Clinical Oncology Pharmacist June 6, 2008 Duke University Hospital School of Nursing

Objectives  List the common toxicities associated with opioid analgesic use  Understand the mechanisms associated with opioid toxicity  Describe pharmacologic and non- pharmacologic means by which to treat and prevent opioid associated toxicities

Opioid Induced Nausea Pathophysiology  Circulating blood opiates activate receptors in the chemoreceptor trigger zone located outside of the blood brain barrier  This transmits a signal to the vomiting center, located in the medulla of the brain Implications  Tolerance to the nauseating effects may occur  Slow titration to a therapeutic dose may decrease likelihood of developing nausea

Opiate Induced Nausea  Prevention Make antiemetics available with opioid prescription and slowly titrate up on doses  Assessment of alternate causes Constipation, CNS pathology, chemotherapy, radiation therapy, GI obstruction  Treatment Consider non-opiates adjuncts as alternatives Antiemetic therapy

Opioid Induced Nausea  Nausea persistent for > 1 week Reassess cause and severity of nausea Change opioid (rotation)  Refractory nausea Persists after above has been tried Reassess cause and severity of nausea Consider neuroaxial analgesia or neuroablative techniques to potentially reduce opiate dose NCCN Practice Guidelines in Oncology - v Adult Cancer Pain

Opioid Induced Sedation  Preventive measures Initiate opioids at lowest possible doses tailored for patient opioid history and clinical status If dose needs to be increased, do so by 25-50% Counsel pts -  dose →  sedation x hrs  Persistent sedation > 1 week after initiation of opioids Evaluate for other causes of sedation  CNS pathology, other sedating medications, hypercalcemia, dehydration, sepsis, hypoxia

Opioid Induced Sedation  Persistent sedation > 1 wk after start Consider ∆ of opioid or ↓ dose to lowest possible Consider adjuvant analgesics Consider lower dose more frequently to ↓ peaks Consider CNS stimulants  Caffeine, methylphenidate, dextroamphetamine, modafinil  Refractory sedation Reassess cause and severity & consider neuroaxial analgesia or neuroablative techniques NCCN Adult Cancer Pain v

Opioid Induced Delirium  Assess for other causes of delirium Hypercalcemia, CNS pathology, brain metastasis, other psychoactive medications  Consider change opiate or adjuvant analgesic to decrease dose  Consider neuroleptic agent Antipsychotics: haloperidol, risperidone, etc NCCN Practice Guidelines in Oncology Adult Cancer Pain v

Opioid Induced Motor and Cognitive Dysfunction  Stable dose of opioids > 2 weeks are not likely to interfere with psychomotor and cognitive function Monitor closely during analgesic administration and titration Patients should not drive during initial titration and should be counseled not to drive x 48 hours after dose increase NCCN Practice Guidelines in Oncology Adult Cancer Pain v

Opioid Toxicity Syndrome  Use of extremely high doses of opioids (> 100 mg/hr morphine or equivalent)  Hyperalgesia, myoclonic jerks, AMS  Dose of opioid  pain not analgesia Associated with dehydration, renal impairment, debilitated patients with advanced disease  Treatment: opioid rotation and NMDA antagonists (methadone or ketamine) NCCN Practice Guidelines Adult Cancer Pain v J Clin Oncol 2007;25(28):

Opioid Induced Respiratory Depression  Use reversal agents sparingly  If respiratory problems or acute MS ∆ Naloxone Intravenous Administration 0.4 mg diluted in 10 mls NS Give 1 ml (0.04mg) Q seconds until improvement in symptoms is noted x 10 minutes Note: half-life of opioid >>> half-life of naloxone  If no response, consider alternative causes of respiratory depression NCCN Adult Cancer Pain v

Opioid Induced Constipation  WD is a 44 yo female admitted to the inpatient 9300 service with abdominal pain  Metastatic gastric cancer (liver, bone) with delays in chemotherapy d/t increased abdominal pain unresponsive to current pain regimen of OxyContin 40 mg TID and prn oxycodone

Opioid Induced Constipation  Other meds on admission included Protonix, ativan, cipro/augmentin, ritalin, zofran, neurontin Senna 1 tab BID, colace, lactulose, fleets  Patient states maintaining hydration & urination, no BM x 7 days PTA  CT abdomen ordered  Chemistries notable for Ca

Opioid Induced Constipation

 Patient CT Scan/KUB suggestive of severe hypercalcemia or opioid induced constipation  Aggressively managed with enemas, oral laxatives, stool softeners, osmotic agents, IV hydration and zometa  Discharged home on same opioid dose and aggressive bowel regimen with instructions

Opioid Induced Constipation Cause  Dehydration, electrolyte abnormalities  Opioid analgesics – directly acting on opioid receptors in the gut  Ondansetron & other agents causing constipation  Chemotherapy agents known to affect nerve conduction in the gut Prevention  Hydration/fluids, exercise  Stool softener Sorbitol, lactulose, docusate, miralax, SMOG enemas  Stimulant laxatives Bisacodyl, senna  Saline laxatives MOM, fleets, mag citrate  Prokinetic agents Metoclopramide

Opioid Induced Constipation Evaluation  Patient history  Listen for bowel sounds  R/O obstruction - Scans  Rectal exam – Impaction?  R/O organic causes Hypercalcemia, treatment related constipation, hydration, hypothyroidism  Peritoneal carcinomatosis  Abdominal adenopathy Treatment  Sorbitol/lactulose 30 ml Q3h x 3 then prn  Bisacodyl mg PO or 10 mg PR daily  Docusate 200 mg BID or Miralax 17 gm po BID  Senna-S 2 tab po BID  “Fiber + Opiate = Brick” NCCN v , J Pain Symptom Manage 2008;35(1):

Opioid Induced Constipation  Methylnaltrexone (naloxone derivative) New kid on the block for treatment and prevention of opioid induced constipation Peripherally-acting mu-opioid receptor antagonist for use in patients with advanced illness receiving palliative care Does not reverse analgesia Contraindicated if patient has bowel obstruction  Typically dosed 8-12 mg (wt based) SQ every other day (up to Q 24 hours) accessed 5/08

Opioid Induced Constipation  Causes intense laxation within 30 minutes of dose Close proximity to proper facilities needed  DC for severe or persistent diarrhea or if need for systemic opioids are eliminated